CPT code 0261U: Colorectal assay, AI immune-risk score2026 Medicare lab fee · Clinical Laboratory Fee Schedule

AI image analysis of colorectal tumor tissue assesses immune features and reports an immune-response and recurrence-risk score.

CMS CLFS 2026 Q4Effective Oct 1, 2026Same amount nationwide

Medicare pays $2,513.25 for 0261U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.

Medicare lab fee · CLFS 2026 Q4

National CLFS amount

$2,513.25

In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.

Geographic adjustment
None
Office vs facility
Same
Since 2022
Unchanged
CMS updates
Quarterly

Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.

On this page 7 sections
  1. Medicare lab fee
  2. What 0261U covers
  3. How it’s paid
  4. Amount history
  5. Similar tests
  6. Billing questions
  7. Sources

What 0261U covers

0261U is an oncology laboratory analysis of colorectal cancer tissue using image analysis and artificial intelligence. It assesses four histologic and immunohistochemical features involving CD3 and CD8 within the tumor core and tumor-stroma border. CD3 and CD8 are assessed in both tissue regions. The result is reported as an immune-response and recurrence-risk score, combining these cellular and immune tissue features. This image-based analysis differs from the seven-gene RT-PCR oncology assay described by 0262U.

Medicare pays 0261U only through the CLFS. For 2026, the national amount is $2,513.25, with one amount applying in every state and locality and no geographic or office/facility adjustment. The code has no physician fee schedule payment; Medicare payment is through the CLFS.

This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.

How Medicare pays 0261U

Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.

One national amount

CMS sets a single Clinical Laboratory Fee Schedule amount for 0261U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.

No office or facility rate

Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.

Updated every quarter

CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.

Not on the physician fee schedule

The physician fee schedule doesn’t list 0261U: Medicare pays the test only from the CLFS.

0261U on the lab fee schedule since 2021

0261U · CLFS 2026 Q4 (current)

$2,513.25

Unchanged since Jan 1, 2022

Amount in each year’s latest CLFS release · bars start at $0

Every change on file

  1. Apr 1, 2024 · CLFS 2024 Q2$4,950.00 → $2,513.25 (−49.2%)
  2. Jan 1, 2023 · CLFS 2023 Q1$2,513.25 → $4,950.00 (+97.0%)
  3. Jan 1, 2022 · CLFS 2022 Q1MAC-priced → $2,513.25

21 quarterly CLFS releases on file, first CLFS 2021 Q4. A code missing from a quarter wasn’t on that release.

0261U compared with similar tests

0262UTumor pathway profileSeven pathway activity score$3,200.00
0262U describes a seven-gene RT-PCR oncology assay, while 0261U analyzes colorectal tumor tissue with AI image analysis.
88360Tumor IHC scoringManual quantitative, per antibody$106.97–$163.58
88360 describes quantitative or semiquantitative tumor immunohistochemistry by antibody; 0261U reports an AI-based immune-response and recurrence-risk score from tissue image analysis.
88342Antibody stainFirst single antibody per specimen$97.65–$150.80
88342 describes an immunohistochemistry service using a single antibody; 0261U reports an integrated image-analysis result based on four tissue features.

0261U billing questions

What does this assay report?

It reports an immune-response and recurrence-risk score based on AI analysis of histologic and immunohistochemical features in colorectal tumor tissue.

What specimen does the assay analyze?

It analyzes colorectal cancer tissue, assessing CD3 and CD8 within the tumor core and at the tumor-stroma border.

How does 0261U differ from 0262U?

0261U is an AI image analysis of colorectal tumor tissue. 0262U describes a seven-gene RT-PCR oncology assay.

Is 0261U the same service as an immunohistochemistry stain code?

No. 0261U describes an integrated image-analysis result based on four histologic and immunohistochemical features; 88360 and 88342 describe immunohistochemistry services.

How does Medicare pay 0261U?

Medicare pays 0261U through the CLFS, with one national amount across localities and no office/facility adjustment. The code has no physician fee schedule payment.

Where this amount comes from

FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.

CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027

Show the CMS file line behind this amount
CLFS row for 0261UPUF_CLFS_CY2026_Q4V1.csv, line 231 (CLFS 2026 Q4)

Open CMS sourceHow we source rates

Did this answer your question about what Medicare pays for 0261U?

Tell us what you were actually trying to work out. We’ll answer you directly, or build the page that does.

Fee sheets · Coming soon

Put 0261U and the rest of your codes on one sheet

Your codes at your locality, with payer contracts beside Medicare.

Join the waitlist